Krystal Biotech Q1 Earnings Call Highlights

3 days ago 2

MarketBeat

Mon, May 4, 2026 astatine 9:38 AM CDT 8 min read

Krystal Biotech logo

Key Points

Krystal reported Q1 nett gross of $116.4 million from VYJUVEK with a 95% gross margin, nett income of $55.9 million, and ended the 4th with much than $1 billion successful currency and investments portion maintaining full‑year non‑GAAP op‑expense guidance of $175–195 million.
U.S. nett income were $87.5 cardinal but showed quarter-to-quarter variability owed to security switchovers and diligent “start‑stop” attraction dosing, portion planetary markets (Europe + Japan) contributed $28.9 cardinal arsenic launches grow and Italy and Spain are targeted for imaginable H2 2026 rollouts.
Krystal expects 2 registrational readouts aboriginal this year—including KB801 (neurotrophic keratitis) and KB803 (DEB corneal abrasions, supporting a Q4 2026 readout)—with further trials (KB407, KB111) advancing and further information updates, including a KB707 update astatine ASCO, slated into 2027.
Interested successful Krystal Biotech, Inc.? Here are 5 stocks we similar better.

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

Krystal Biotech (NASDAQ:KRYS) reported first-quarter 2026 nett gross of $116.4 cardinal from planetary income of VYJUVEK, supported by continued request successful the U.S. and aboriginal traction successful Europe and Japan. Management highlighted affirmative operating leverage, a 95% gross margin, and an expanding objective pipeline with aggregate information readouts expected aboriginal this year.

VYJUVEK gross maturation continues arsenic planetary publication expands

Chairman and CEO Krish Krishnan said the institution delivered “another 4th of planetary gross growth,” with Q1 nett VYJUVEK gross of $116.4 cardinal and cumulative nett gross since motorboat exceeding $846 million. Krishnan noted the 4th represented 9% sequential maturation versus the 4th fourth of 2025 contempt “a higher than accustomed level of security changes” emblematic of archetypal quarters for commercial-stage biotech companies.

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Krystal Clear: Krystal Biotech Clears Resistance successful Good Volume

Chief Accounting Officer Kathryn Romano said Q1 nett gross accrued 32% compared to the archetypal 4th of 2025. Cost of goods sold was $6.3 million, and gross borderline was 95%, somewhat up from 94% a twelvemonth earlier. Romano attributed the borderline show to manufacturing process improvements for the U.S.-approved merchandise and said the institution is moving to execute akin efficiencies for different markets.

International markets accounted for a meaningful information of the quarter. Laurent Goux, EVP and wide manager for Europe, said Europe positive Japan contributed $28.9 cardinal successful nett revenue. He estimated that much than 140 dystrophic epidermolysis bullosa (DEB) patients person been prescribed VYJUVEK crossed Germany, Japan, and France, citing expanding doc engagement and a broadening prescriber base.

Read Entire Article